Söndag 27 April | 04:36:36 Europe / Stockholm
Svenska | English
Investor Relations
Public Relations

Amniotics

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Prenumeration

Kalender

Est. tid*
2025-02-18 - Bokslutskommuniké 2024
2024-09-28 - 15-6 2024
2024-08-20 - Kvartalsrapport 2024-Q2
2024-07-15 - Extra Bolagsstämma 2024
2024-05-23 - X-dag ordinarie utdelning AMNI 0.00 SEK
2024-05-22 - Årsstämma
2024-02-23 - Bokslutskommuniké 2023
2023-11-27 - 15-10 2023-Q3
2023-10-03 - Extra Bolagsstämma 2023
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-23 - X-dag ordinarie utdelning AMNI 0.00 SEK
2023-05-22 - Årsstämma
2023-02-19 - Bokslutskommuniké 2022
2023-02-17 - Extra Bolagsstämma 2022
2022-11-30 - Kvartalsrapport 2022-Q3
2022-08-16 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning AMNI 0.00 SEK
2022-05-19 - Årsstämma
2022-05-10 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-12 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
SektorHälsovård
IndustriBioteknik
Amniotics är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling av diverse läkemedelskandidater. Produktportföljen inkluderar exempelvis stamcellsbaserade terapier för att behandla allvarliga livshotande sjukdomar, där effektiv behandling saknas eller är otillräcklig. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro i Sverige och har sitt huvudkontor i Lund.
Amniotics to present CogniStem results at international stem cell symposium
2023-05-10 15:00:00

Amniotics AB (publ) (Nasdaq Stockholm: AMNI) announces today that the company will present results from the development project CogniStem at Cold Spring Harbor Laboratory (CSHL) Symposium on Quantitative Biology focused on stem cells.

The stem cell symposium is arranged by Cold Spring Harbor Laboratory (CSHL) at Long Island, and will take place May 31 - June 4, 2023.

Amit Saxena, PhD, will present the results of Amniotics mesenchymal stem cell project CogniStem.

About CogniStem™

CogniStem is a neuro specific stem cell product of neonatal origin, derived from full-term amniotic fluid. CogniStem is expected to be efficacious in various central nervous system (CNS) diseases through modulation of the immune response and by supporting the recovery process.

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

About Amnioitics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.
Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.
Amniotics is headquartered in Lund, Sweden.
The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB, e post: certifiedadviser@redeye.se.
Learn more at www.amniotics.com. 

Attachments

Amniotics to present CogniStem results at international stem cell symposium

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden